Dr. Marc Hansen

Dr. Hansen received his B.S. from Brigham Young University in 1997 and his PhD from the Cancer Biology program Stanford University in 2002 before becoming an academic PI in the Department of Physiology and Developmental Biology at Brigham Young University in 2005. His academic research was focused on cytoskeletal system and their contribution to cancer progression, specifically epithelial-mesenchymal transitions (EMT) that drive cancer metastasis. He has published over 30 articles that demonstrate an unusually broad use of different scientific approaches, from biochemistry to imaging to computational modeling. Dr Hansen spent a year as a visiting Scientist at Imperial College London in 2012-13. He developed the proprietary phenotypic screening technology and founded Frost Biologic to commercialize this idea by generating novel anticancer drugs.

Dr. Adam Siddiqui-Jain

Dr. Siddiqui-Jain brings more than fifteen years of professional drug discovery experience, primarily focused in oncology, to Frost Biologic.  He previously held the position of Associate Director of Experimental Biology and Screening at Cylene Pharmaceuticals, where he was the lead project scientist on several oncology drug discovery programs.  Two of these programs successfully yielded clinical candidates, Quarfloxin (phase 1) and the first-in-class protein Kinase CK2 inhibitor CX-4945 (phase 1).  Prior to his arrival at Cylene Pharmaceuticals, Dr. Siddiqui-Jain worked in Laurence Hurley’s Lab at the University of Arizona, where he discovered the active conformation of the G-quadruplex DNA regulatory structure in the c-Myc promoter and is the first-named author on the subsequent PNAS paper (2002) that has since been referenced more than 650 times.  Dr. Siddiqui-Jain holds a Ph.D. in Biological Chemistry and has published more than 40 publications and patents. Adam is director of Chemistry at Tolero Pharmaceuticals.

Dr. Stewart Chipman

Dr. Chipman is a biotech executive with over 20 years of experience in building and leading scientific teams focused on the discovery and development of novel human therapeutics in the fields of inflammation, metabolic bone diseases, and oncology.  Currently Dr. Chipman is Chief Scientific Officer & President of Aequus BioPharma, Inc., where he co-founded the company and is a co-inventor of Aequus’ GlycoPolymer technology platform.  He was previously Vice President of Research at Cell Therapeutics Inc. where he lead a multi-national team developing multiple novel oncology drug candidates, Director of Biomolecular Screening at Immunex where his team provided expertise in assay development, high-throughput screening robotics and synthetic chemistry to enable several small molecule lead discovery and optimization programs, and Director of Biology at ArQule in Boston.  Prior to pursuing his career in biotechnology Dr. Chipman was an Associate Professor of Medicine at The Johns Hopkins University School of Medicine.  Dr. Chipman received his B.S. in Biology at Boston University and Ph.D. in Biochemistry from the Boston University School of Medicine.  He has co-authored more than 40 peer-reviewed scientific papers and is a co-inventor on eight U.S. and foreign patents.


Dr Nadauld earned an MD/PhD from the University of Utah in 2009 and a medical oncology specialization at Stanford University in 2013. He remains a Consulting Assistant Professor at the Stanford University School of Medicine, but his primary appointment is as the Director of Cancer Genomics at Intermountain Healthcare, where he maintains an active and highly recognized clinical practice and clinical research program. He has entrepreneurial experience as a founder of TOMA Biosciences and advises NAVICAN. Dr Nadauld sits on the board of directors for the Gastric Cancer Foundation.